• Home
• Research
• Public Engagement
• Find a Clinical Trial

Cardiology

AEGIS-II: Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

• Condition: Acute Coronary Syndrome
• Website: NCT03473223
• Sponsor: CSL Behring
• Location: Saint John Regional Hospital
• Horizon Principal Investigator: Dr. Sohrab Lutchmedial
• To participate, call the research coordinator at: 506-648-7986 and refer to study file #10118

ARTESiA: Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub-Clinical Atrial fibrillation

The purpose of this study is to determine which treatment is best for preventing stroke or systemic embolism in patients who have experienced at least one episode of sub-clinical atrial fibrillation (SCAF) detected by their pacemaker, intracardiac defibrillator (ICD) or insertable cardiac monitor (ICM) and also have other risk factors for stroke. We will also assess whether these treatments protect against smaller changes in brain function for people who do not have stroke.

• Condition: Atrial Fibrillation, Stroke
• Website: NCT01938248
• Sponsor: Population Health Research Institute
• Location: Saint John Regional Hospital
• Horizon Principal Investigator: Dr. Satish Toal
• To participate, call the research coordinator at: 506-648-7986 and refer to study file #10127

SAFE-STEMI for Seniors: Study of Access Site for Enhancing PCI in STEMI in Seniors

The purpose of this study is to investigate several different ways to care for patients at least 60 years old who are having this type of heart attack. The study involves devices such as stents and wires that measure blood pressure in the heart arteries and different types of artery access (a type of small plastic tube that is placed in the leg or wrist). The Medtronic Resolute® Family of stents and Volcano Verrata®, Verrata Plus® wires that will be used during this study have been approved to be sold in the US by the Food and Drug Administration (FDA) and by Health Canada. They are often used by doctors in the usual care of myocardial infarction (heart attack). However, these devices have not been approved by FDA and Health Canada for use in heart attack patients. Participation in the study will help to collect evidence about how they can be used safely and effectively in patients to improve outcomes from a heart attack.

• Condition: Myocardial infarction
• Website: NCT02939976
• Sponsor: Dr. David F. Kong
• Location: Saint John Regional Hospital
• Horizon Principal Investigator: Dr. Sohrab Lutchmedial
• To participate, call the research coordinator at: 506-648-7986 and refer to study file #10143

BRAIN-AF: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

This is a prospective, multicenter, randomized, double-blinded clinical trial exploring the efficacy and safety of rivaroxaban as compared to standard of care in reducing stroke, transient ischemic attack (TIA) and neurocognitive decline, in subjects with non-valvular AF and with low risk of stroke.

• Condition: Atrial fibrillation
• Website: NCT02387229
• Sponsor: Montreal Heart Institute
• Location: Saint John Regional Hospital
• Horizon Principal Investigator: Dr. Ricardo Bessoudo
• To participate, call the research coordinator at: 506-648-7986 and refer to study file #10152

RASTA AF: Reversal Of Atrial Substrate to Prevent Atrial Fibrillation

The purpose of this study is find out if patients with risk factors for atrial fibrillation (AF) will benefit from a treatment strategy that combines risk factor modification with catheter ablation, versus catheter ablation only.

• Condition: Atrial fibrillation
• Website: NCT03682991
• Sponsor: Nova Scotia Health Authority
• Location: Saint John Regional Hospital
• Horizon Principal Investigator: Dr. Satish Toal
• To participate, call the research coordinator at: 506-648-7986 and refer to study file #100309

Risk Estimation Following Infarction, Non-invasive Evaluation - ICD efficacy (REFINE - ICD)

The purpose of the REFINE ICD study is to test whether a device called an implantable cardioverter defibrillator (ICD) can increase the likelihood of survival in patients at risk of heart rhythm irregularities, as determined from a 24-hour heart monitor that is performed within at least 2 months to 5 years after a heart attack.

• Condition: Myocardial infarction
• Website: NCT00673842
• Sponsor: University of Calgary
• Location: Saint John Regional Hospital
• Horizon Principal Investigator: Dr. Satish Toal
• To participate, call the research coordinator at: 506-648-7986 and refer to study file #10214